Core Opinion - Bright Minds Biosciences Inc. is focused on developing highly selective 5-HT2 agonists for treating drug-resistant epilepsy, depression, and other CNS disorders, and is hosting a virtual R&D Day featuring key opinion leaders in the field of absence seizures [1][5]. Group 1: Key Opinion Leaders - Featured speakers include Dennis Dlugos, MD, a professor of neurology and pediatrics with extensive experience in pediatric neurology and epilepsy [2]. - Wendyl D'Souza, MBChB, MPH, FRACP, PhD, is a neurologist and epilepsy specialist with over twenty years of experience, focusing on idiopathic generalized epilepsies and antiseizure medications [3]. - Alexander Rotenberg, MD, PhD, is a neurologist and epileptologist leading efforts in non-invasive brain stimulation methods for pediatric epilepsy [4]. Group 2: Company Initiatives - Bright Minds will review the therapeutic rationale for BMB-101 and discuss the BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating BMB-101's safety, tolerability, and efficacy in adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy [5]. - The company is developing innovative treatments targeting neurological and psychiatric disorders, with a pipeline that includes novel compounds for conditions with high unmet medical needs [7]. - Bright Minds has created a unique platform of highly selective serotonergic agonists, providing a rich portfolio of new chemical entity programs within neurology and psychiatry [8].

Core Insights - Bright Minds Biosciences Inc. announced positive findings from its DBA/2 mouse model study, where BMB-101 demonstrated a complete elimination of drop attacks, indicating its potential as a treatment for drug-resistant epilepsy [1][2] Group 1: Study Findings - BMB-101 showed dose-dependent efficacy in the DBA/2 mouse model, achieving 100% survival and reversing brainstem serotonin deficits, which is crucial for preventing seizure-induced respiratory arrest [2][3] - The DBA/2 mouse model is recognized for its predictive value regarding sudden unexpected death in epilepsy (SUDEP), highlighting the importance of BMB-101 in addressing this critical gap in SUDEP prevention [8] Group 2: Drug Mechanism and Development - BMB-101 is a novel scaffold 5-HT2C Gq-protein biased agonist designed for chronic treatment of neurological disorders, specifically targeting the Gq-protein signaling pathway to minimize receptor desensitization and tolerance [4] - In Phase 1 clinical studies, BMB-101 was safe and well-tolerated among 64 healthy volunteers, with no serious adverse events reported [5] Group 3: Target Engagement and Efficacy - An extensive target-engagement study confirmed robust central target engagement through both fluid and physical biomarkers, indicating a qEEG signature typical for anti-epileptic drugs [6] - BMB-101 has demonstrated efficacy in preclinical studies for conditions such as Dravet Syndrome and generalized seizures, suggesting its potential for sustained seizure relief in difficult-to-treat patient populations [4][6] Group 4: Company Overview - Bright Minds is focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting key receptors in the brain [7][9]